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Randomized trialBackground and purpose: To report the long-term results of a single-institution randomized study com-
paring the results of breast-conserving treatment with partial breast irradiation (PBI) or conventional
whole breast irradiation (WBI).
Patients and methods: Between 1998 and 2004, 258 selected women with pT1 pN0-1mi M0, grade 1–2,
non-lobular breast cancer without the presence of extensive intraductal component and resected with
negative margins were randomized after BCS to receive 50 Gy WBI (n = 130) or PBI (n = 128). The latter
consisted of either 7  5.2 Gy high-dose-rate (HDR) multi-catheter brachytherapy (BT; n = 88) or 50 Gy
electron beam (EB) irradiation (n = 40). Primary endpoint was local recurrence (LR) as a ﬁrst event. Sec-
ondary endpoints were overall survival (OS), cancer-speciﬁc survival (CSS), disease-free survival (DFS),
and cosmetic results.
Results: After a median follow up of 10.2 years, the ten-year actuarial rate of LR was 5.9% and 5.1% in PBI
and WBI arms, respectively (p = 0.77). There was no signiﬁcant difference in the ten-year probability of
OS (80% vs 82%), CSS (94% vs 92%), and DFS (85% vs 84%), either. The rate of excellent-good cosmetic
result was 81% in the PBI, and 63% in the control group (p < 0.01).
Conclusions: Partial breast irradiation delivered by interstitial HDR BT or EB for a selected group of early-
stage breast cancer patients produces similar ten-year results to those achieved with conventional WBI.
Signiﬁcantly better cosmetic outcome can be achieved with HDR BT implants compared with the out-
come after WBI.
 2013 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 108 (2013) 197–202
Open access under CC BY-NC-ND license. Over the last three decades, breast-conserving therapy (BCT)
including surgical removal of the primary tumor and whole breast
irradiation (WBI) consisting of 5 weeks of external beam radiother-
apy (EBRT) with or without an additional 1–2 weeks of boost irra-
diation to the tumor bed, became the standard of care for the
treatment of early-stage breast carcinoma [1–3]. However, the
necessity of giving WBI for all patients as a part of BCT has been
questioned, and accelerated partial breast irradiation (APBI) has
been tested in multiple clinical trials as an alternative treatment
option [4–31]. The results of multiple phase I–II trials showed that
APBI using interstitial multi-catheter brachytherapy (BT) using
adequate patient selection and quality assurance (QA) yields simi-
lar results to those achieved with conventional WBI [4,11–
14,19,20,23–25,28]. However, two randomized APBI trials con-
ducted in the late eighties showed inferior results with partial
breast irradiation (PBI) using less sophisticated EBRT techniquesand limited QA procedures [7,15]. Therefore, the hypothesis that
PBI produces similar results to those achieved with standard WBI
should be proved in prospective randomized trials.
At the Hungarian National Institute of Oncology, a prospective
phase III clinical trial comparing PBI with multi-catheter intersti-
tial high-dose-rate (HDR) BT or EBRT with WBI for a selected group
of early-stage breast cancer patients was conducted between 1998
and 2004. Five-year results of this study have been published else-
where, and this is the ﬁrst report of the ten-year results [18].
Materials and methods
Study design
Between July 1998 and May 2004, 258 patients with stage I–II
breast cancer who underwent breast-conserving surgery (BCS)
were randomized to receive WBI (n = 130) or PBI (n = 128). Patients
were eligible if they met all the following conditions: wide excision
with microscopically negative surgical margins; unifocal tumor;
primary tumor size 620 mm (pT1); cN0, pN0, or pN1mi (nodal
198 Long-term results of partial versus whole breast irradiationmicrometastasis 62 mm) axillary nodal status; and histological
grade 1–2. Exclusion criteria included prior breast cancer or other
malignancies (except skin basalioma); bilateral breast carcinoma;
pure ductal or lobular carcinoma in situ (pTis); invasive lobular car-
cinoma; lymphovascular invasion; or the presence of an extensive
intraductal component. Young women aged 640 years were also
excluded after a protocol amendment performed in 2001.
Randomization was done by the principal investigator. Patients
were randomly allocated to treatment options by a sealed-enve-
lope system in blocks of ten. Blinding of physicians performing
treatments and follow-up and of patients was not possible for
technical reasons. No stratiﬁcation was used. The primary endpoint
for analysis was the appearance of local recurrence (LR) as a ﬁrst
event. The scientiﬁc hypothesis was ‘‘non-relevant non-inferiority’’
of PBI with regard to LR. The difference in LR between the two arms
that we considered clinically non-relevant for our sample size cal-
culation was 6% (e.g. 10% after PBI vs 4% after WBI at ﬁve years).
The 4% ﬁgure was considered as the low ceiling of ﬁve-year LR
rates reported in modern breast-conserving series using WBI. The
originally planned sample size (n = 570) was calculated to detect
this 6% difference in LR rate at ﬁve years between the two treat-
ment arms with a statistical power of 80% and at a signiﬁcance
level of 5%. Accrual was stopped prematurely at a sample size of
258 patients, because since June 2004 all eligible patients have
been offered to participate in the European multicentric GEC-
ESTRO (Groupe Européen de Curiethérapie-European Society for
Therapeutic Radiology and Oncology) phase III APBI trial. One
patient in the WBI arm developed distant metastasis before RT
and did not receive the assigned treatment. Another patient in
PBI arm refused her assigned therapy and underwent mastectomy
without RT. However, all patients were analyzed according to the
intent to treat policy (Fig. 1). The trial protocol was accepted by
the ethics committee of the National Institute of Oncology, Buda-
pest, and informed consent of the patients was required.Surgery
All patients underwent BCS with axillary dissection (n = 160) or
sentinel lymph node biopsy (n = 93), while surgical axillary stagingAnalyzed as randomised (n = 130)
Excluded from analysis  (n = 0)
Lost to follow-up  (n = 2)
Reason: patients declined follow-up 
at 18th and 22th months after surgery.
Allocated to WBI (n = 130)
Received allocated treatment (n = 129)
Did not receive allocated treatment (n = 1)
Reason: Patient identified with distant 
metastasis before RT.
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Fig. 1. CONSORT trial ﬂow diagram. Abbreviations: WBI – whole breawas omitted in 5 cases, based on the surgeon’s preference. During
surgery, the boundaries of the excision cavity were marked with
titanium clips. All breast specimens were inked and oriented by
the pathologist to deﬁne microscopic margins. Patient and tumor
characteristics are listed in Table 1.Radiotherapy
Eighty-eight out of 128 (69%) patients in the PBI arm were
assigned to be treated with 7  5.2 Gy b.i.d. HDR multi-catheter
interstitial BT alone, but the protocol allowed 50 Gy limited-ﬁeld
EB irradiation for patients who were technically unsuitable for
interstitial implantation (n = 40; 31%). Implantations were per-
formed four to six weeks after BCS under local anesthesia. Patients
were treated with HDR remote after-loading equipment using a
192Ir stepping source. The traditional Paris system guidelines were
used for the planning of the implant geometry [32]. A preimplant
radiograph simulation was performed by using a template placed
on the breast to determine the entrance and exit points of the nee-
dles from the ‘‘needle-eye’’ view. Planning target volume (PTV) was
deﬁned as the excision cavity delineated by the surgical clips plus a
margin of 2 cm. However, only a 1–1.5 cm safety margin was
applied when excision cavity was close to the skin surface or chest
wall. Four to thirteen (median: 9) guide needles were inserted into
the tumor bed in a triangular geometry using template guidance.
The spacing between the needles was 13 or 15 mm. Then, the guide
needles were replaced with ﬂexible plastic catheters, which were
ﬁxed with buttons. Single-, double-, triple-, and four-plane
implants were performed at 1 (1%), 47 (54%), 38 (44%), and 1
(1%) patients, respectively. The Paris system rules were not used
for dose prescription [32]. Our own planning concepts have been
established to achieve more conformal coverage of the PTV. The
treatment planning was based on a three-dimensional reconstruc-
tion of the locations of the catheters, surgical clips, and skin points
digitized from two postimplant radiograph ﬁlms taken with the
variable-angle reconstruction technique. The active source posi-
tions and reference dose points were deﬁned individually in each
catheter, and the optimization of the dwell times to dose points
and geometry was performed. The most peripheral active sourceExcluded  (n = 0)
Lost to follow-up  (n = 0)
Allocated to PBI (n = 128)
Received allocated treatment (n = 127)
Did not receive allocated treatment (n = 1)
Reason: Patient opted for mastectomy 
without RT.
Analyzed as randomised (n = 128)
Excluded from analysis  (n = 0)
n
s
p
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n
st irradiation; PBI – partial breast irradiation; RT –radiotherapy.
Table 1
Patient and tumor characteristics by treatment arms.
Characteristic PBI (n = 128) WBI (n = 130) p-Value
Mean age (years) 59 58 0.31b
Range 30–84 31–80
Age groups (years) 0.23
640 3 (2.4) 6 (4.6)
41–50 26 (20.3) 26 (20.0)
51–60 41 (32.0) 50 (38.5)
>60 58 (45.3) 48 (36.9)
Premenopausal 27 (21.1) 28 (21.5) 0.93
Pathological tumor size (mm) 0.14
65 8 (6.2) 3 (2.3)
>5 but 610 39 (30.5) 35 (26.9) 0.13b
>10 but 620 81 (63.3) 92 (70.8)
Median 13 13
Pathological nodal status 0.25
pN0 121 (94.5) 123 (94.6)
pN1mi 3 (2.3) 6 (4.6)
Not known (no axillary surgery) 4 (3.2) 1 (0.8)
Surgical margins 0.78
Close (<2 mm) 0 (0) 1 (0.8)
Clear (P2 mm) 123 (96.1) 123 (94.6)
Clear (NSABP)a 5 (3.9) 6 (4.6)
Histologic type 0.52
Ductal 103 (80.5) 108 (83.1)
All others 25 (19.5) 22 (16.9)
Tumor grade 0.03
1 81 (63.3) 65 (50)
2 47 (36.7) 65 (50)
ER status 0.42
Positive 116 (90.6) 113 (86.9)
Negative 10 (7.8) 16 (12.3)
Unknown 2 (1.6) 1 (0.8)
Abbreviations: PBI – partial breast irradiation; WBI – whole breast irradiation; ER –
estrogen receptor. Data are n (%).
a National Surgical Adjuvant Breast and Bowel Project criteria, no tumor on ink.
b Mann–Whitney two-sample test. All other variables were tested with the chi-
square test.
C. Polgár et al. / Radiotherapy and Oncology 108 (2013) 197–202 199positions were kept at a minimum of 10–15 mm from the skin sur-
face, limiting the maximal skin dose to 60% of the prescribed dose.
The distances of the dose points from the catheters were 4–12 mm
and could vary from catheter to catheter. The prescribed BT dose,
calculated to the 100% isodose surface was 36.4 Gy and delivered
with seven fractions of 5.2 Gy, each given at least six hours apart
within four days. For the assessment of implant quality, cumula-
tive dose-volume histograms and dose-nonuniformity ratios
(DNR) were used [33]. The mean volume encompassed by the
100% isodose surface (Vref) was 63 cm3 (range: 27–120 cm3). The
mean DNR was 0.38 (range: 0.21–0.63). Postimplant CT scans were
performed for only 17 of 87 patients (20%) to document PTV cover-
age and to develop CT-image based BT planning techniques later
[33]. Eighty-ﬁve out of 88 patients (97%) received the intended
dose of BT. At one patient only six fractions of 5.2 Gy were deliv-
ered because of grade 3 acute skin toxicity. Another patient was
treated with an off-protocol fractionation scheme (ﬁve fractions
of 6.64 Gy b.i.d.) based on the decision of the treating radiation
oncologist. One patient refused BT, as she opted for mastectomy
instead of RT. All BT patients received antibiotics during the treat-
ment period plus two days, thereafter. After the last treatment
fraction the catheters were removed.
Electron beam PBI (n = 40) was performed using 6–15 MeV en
face electron ﬁelds to the tumor bed extended with a margin of
2 cm. In the case of deep-seated tumor bed a smaller safety mar-
gin was used in the direction of the pectoral muscle to avoid
irradiation of the lung tissue. Adequate ﬁeld size and beam
energy were deﬁned by CT-based treatment planning and/or
simulation radiographs. The median total dose was 50 Gy (range:42–50 Gy) using conventional fractionation (2 Gy/day, ﬁve frac-
tions/week).
In the control arm, WBI was delivered with telecobalt (n = 29)
or 6–9 MV photon (n = 100) beams using wedged tangential ﬁelds
with 2 Gy daily fractions over ﬁve weeks. Two dimensional CT-
based treatment planning was used for all patients. Three dimen-
sional conformal (3D-CRT) or intensity modulated radiotherapy
(IMRT) were not available in that era. One patient (0.8%) was iden-
tiﬁed with distant metastasis and received palliative systemic
treatment instead of WBI. The median total dose of WBI for the
other 129 patients was 50 Gy (range: 42–50 Gy). Only one patient
(0.8%) received 16 Gy additional electron boost to the tumor bed.
Regional nodal irradiation was not given.Adjuvant systemic therapy
Adjuvant systemic therapy was given according to the actual
institutional treatment protocol. Since 1999, all patients with
tumor size >10 mm received adjuvant systemic therapy. Eighty-
nine of 128 (70%) PBI and ninety-four of 130 (72%) WBI patients
received chemo- and/or hormone therapy (p = 0.37). Hormone
therapy consisted of aromatase inhibitors in 23 (18%) and 24
(18%) patients, or tamoxifen in 64 (50%) and 68 (52%) women with
goserelin acetate in 15 (12%) and 13 (10%) cases, respectively. Only
7 patients received adjuvant chemotherapy including 6 cycles of
CMF in 1 (0.8%) and 2 (1.5%) patients or 4 cycles of AC in 1 (0.8%)
and 3 (2.3%) women, respectively. An additional patient in the
WBI arm was identiﬁed with distant metastasis and received palli-
ative chemo- and hormone therapy instead of RT.Follow-up
Patients were seen every three months in the ﬁrst two years
after RT, every six months in the next three years, and annually
thereafter. Baseline mammography was performed six months
after completion of RT and yearly, thereafter. Local recurrence
was deﬁned as any detection of cancer in the treated breast occur-
ring as a ﬁrst event, proved by histological examination in every
case. An elsewhere breast failure (EF) was deﬁned as ipsilateral
LR detected at least 2 cm from the surgical clips. All other LR was
classiﬁed as true recurrence/marginal miss (TR/MM). Cosmetic
outcome was assessed by the treating radiation oncologist and/or
the principal investigator at each follow-up. The cosmetic results
were scored using the Harvard criteria for those patients who
received at least one fraction of the assigned treatment (n = 256)
[34]. The last available follow-up data were used for the analysis
of cosmetic results. Data on cosmetic outcome were available for
241 patients (94%), and registered at a median follow-up of
124 months (range: 18–162 months).Statistical methods
Survival analyses were based on the intent to treat principle
with event-free intervals deﬁned as the time between the date of
surgery and the date of event or last follow-up. The statistical test
used to perform power calculation for ‘‘non-relevant non-inferior-
ity’’ was one-sided. Accrual was closed before reaching the origi-
nally planned sample size (n = 570). According to our reanalysis
of power for the actual sample size (n = 258), our study has an
80% power to detect a 10% difference between the arms.
Discrete pretreatment variables of the two arms were compared
using the chi-square test. Continuous variables were evaluated
using the Mann–Whitney two-sample test. Survival curves were
calculated using the Kaplan–Meier method and compared with
two-sided log-rank test. A probability level of 0.05 was considered
to be statistically signiﬁcant. The probability of events obtained
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intervals (CI). Differences in cosmetic outcome between treatment
groups were compared using the Fisher’s exact test. The SOLO soft-
ware (Department of Biometrics, University of California, Los Ange-
les, CA) was used for statistical analyses.0 24 48 72 96 120 144 168
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Fig. 2. Time to local recurrence by Kaplan–Meier estimates. Abbreviations: WBI –
whole breast irradiation; PBI – partial breast irradiation.Results
Median follow-up of all and surviving patients were 10.2 years
(range: 1.5–13.5 years) and 10.8 years (range: 7.6–13.5 years),
respectively. During the follow-up period 48 patients (19%) have
died, and only 2 (0.8%) have been lost to follow up. Overall, 7
(5.5%) and 6 (4.6%) patients developed LR as a ﬁrst event in the
PBI and WBI arm, respectively. The crude rates of ﬁrst events
according to treatment arms are summarized in Table 2. The ﬁve-
and ten-year actuarial survival rates are presented in Table 3. The
ten-year probability of LR-free survival was similar in the two
treatment arms (Fig. 2). The ten-year actuarial rate of LR, TR/MM,
and EF was 5.9% (95% CI 1.6–10.2%), 2.4% (95% CI 0–5.1%), and
3.5% (95% CI 0.1–6.9%) after PBI, whereas it was 5.1% (95% CI 1.1–
9.1%), 3.4% (95% CI 0.1–6.7%), and 1.6% (95% CI 0–3.9%) after WBI,
respectively. The ten-year probability for developing regional
recurrence after PBI and WBI was 2.5% (95% CI 0–5.3%), and 1.7%
(95% CI 0–4.0%), respectively. Overall survival (OS), cancer-speciﬁc
survival (CSS), and disease-free survival (DFS) at ten years for PBI
was 79.7% (95% CI 72.5–86.9%), 94.4% (95% CI 89.9–98.9%), and
85.3% (95% CI 79.0–91.6%), respectively, whereas for WBI it was
82.1% (95% CI 75.5–88.7%), 91.7% (95% CI 86.8–96.6%), and 83.6%
(95% CI 77.0–90.2%).
Six out of seven patients with LR in the PBI group were salvaged
with repeated BCS. Four of them received WBI up to a total dose of
45–50.4 Gy. One patient developed subsequent lung metastasisTable 2
Incidence of ﬁrst events according to treatment arms.
Event PBI (n = 128) WBI (n = 130)
Ipsilateral breast failure
Tumor bed recurrence/marginal miss
Elsewhere breast failure
7 (5.5)
3 (2.4)
4 (3.1)
6 (4.6)
4 (3.1)
2 (1.5)
Regional failure
Axillary failure
Supraclavicular failure
3 (2.3)
2 (1.5)
1 (0.8)
1 (0.8)
1 (0.8)
0 (0)
Distant metastasis 7 (5.5) 11 (8.5)
Any ﬁrst relapsea 17 (13.3) 18 (13.8)
Contralateral breast cancer 9 (7.0) 8 (6.2)
2nd Primary tumor 7 (5.5) 6 (4.6)
Non-breast cancer death 10 (7.8) 10 (7.7)
Abbreviations: PBI – partial breast irradiation; WBI – whole breast irradiation. Data
are n (%).
a Local, regional, or distant failure, whichever came ﬁrst.
Table 3
Actuarial 5- and 10-year survival rates by treatment arm.
Event PBI vs WBI
5-year rate
PBI vs WBI
10-year rate
p-
Value
Ipsilateral breast failure 4.0% vs 3.3% 5.9% vs 5.1% 0.77
Tumor bed recurrence/marginal
miss
1.6% vs 1.6% 2.4% vs 3.4% 0.72
Elsewhere breast failure 2.4% vs 1.6% 3.5% vs 1.6% 0.41
Contralateral breast cancer 6.4% vs 2.4% 8.3% vs 6.4% 0.56
Regional failure 1.6% vs 1.7% 2.4% vs 1.7% 0.65
Distant metastasis 6.4% vs 6.3% 7.3% vs 11.5% 0.61
Disease-free survival 88.8% vs
90.5%
85.3% vs
83.6%
0.97treated with hormone therapy and was alive with stable disease
at the time of analysis. Second LR occurred only for one patient,
treated with chemotherapy followed by trastuzumab yielding par-
tial response and breast cancer death later. The other four patients
were alive without any further relapse. In the PBI group only one
woman underwent successful salvage mastectomy.
Among the six patients with LR in the WBI group, three were
salvaged with lumpectomy, and three with mastectomy. One of
them developed distant metastasis and died of the disease later.
The other ﬁve women were alive without any further relapse. Sec-
ond LR did not occur.
Cosmetic outcome according to the RT technique is listed in
Table 4. The rate of excellent-good cosmetic result was 81% in
the PBI arm and 63% in the WBI arm (p < 0.01). The rate of excel-
lent-good cosmesis in the PBI group was 85% after HDR BT and
72.5% after EB (p = 0.97), whereas in the WBI group it was 67%
using 6–9 MV photons and 48% using telecobalt (p = 0.08). Exclud-
ing EB PBI and telecobalt WBI patients from the analysis, signiﬁ-
cantly more patients treated with HDR BT had excellent-good
cosmetic result compared to those treated with 6–9 MV photon
WBI (85% vs 67%; p < 0.01). Analysis of late radiation side effects
will be reported elsewhere.Discussion
APBI is an attractive treatment approach that shortens the 5–
7 week course of conventional WBI to one week or less focusing
ionizing radiation just to the vicinity of the tumor bed and avoiding
irradiation of the surrounding healthy breast tissue. The accelera-
tion of RT eliminates some of the disadvantages of the extended
treatment period, especially for elderly patients, working women,
and those who live at a signiﬁcant distance from the RT facility.Table 4
Cosmetic outcome.
Harvard
cosmetic
score
PBI – HDR BT
(n = 85)a
PBI – EB
(n = 40)a
WBI –
photons
(n = 93)a
WBI – cobalt
(n = 23)a
Excellent 29 (34.1) 7 (17.5) 16 (17.2) 3 (13.1)
Good 43 (50.6) 22 (55.0) 46 (49.5) 8 (34.8)
Fair 11 (12.9) 11 (27.5) 22 (23.6) 11 (47.8)
Poor 2 (2.4) 0 (0) 9 (9.7) 1 (4.3)
Abbreviations: PBI – partial breast irradiation; HDR BT – high-dose-rate brachy-
therapy; EB – electron beam; WBI – whole breast irradiation. Data are n (%).
a n = patient number with data available on cosmetic outcome.
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EBRT techniques has been intensively evaluated in prospective
clinical studies as a possible alternative to WBI (Table 5). The
results of these trials were controversial. Majority of phase II BT tri-
als – using strict patient selection criteria and proper treatment
technique – were successful in yielding an annual LR rate in the
range of 0–1.2% [4,11–14,19,20,23–25,28]. On the other hand,
results of early trials using out-of-date BT or EBRT techniques
without rigorous QA procedures for mainly unselected patients
were poor [7–9,15,17,22]. These results suggest that APBI is a rea-
sonable approach at least for a properly selected subgroup of early-
stage breast cancer patients, provided that meticulous attention is
paid to QA [21].
In the last decade, based on the promising results with acceler-
ated multi-catheter partial breast BT, new APBI techniques includ-
ing external beam three-dimensional conformal radiotherapy (3D-
CRT), intraoperative RT, and intracavitary BT have been developed
and implemented [5,6,10,16,26,27,29]. According to the ﬁrst pub-
lished series, the ﬁve-year results are encouraging with both 3D-
CRT and intracavitary balloon BT (Table 5) [5,10,16]. On the other
hand, in a recent large retrospective population-based cohort
study, treatment with breast BT compared with WBI was associ-
ated with signiﬁcantly higher ﬁve-year incidence of subsequent
mastectomy (4% vs 2.2%), and postoperative complications (28%
vs 17%) [30]. In addition to the limitations associated with such
retrospective comparative effectiveness studies, it should be noted
that 77% of BT patients were treated with intracavitary BT using
single-entry balloon applicators. In contrast, in our prospective
randomized trial only one patient (0.8%) in the PBI arm, and three
(2.3%) in the WBI arm underwent subsequent mastectomy. There-
fore, the results and conclusions obtained from the retrospective
study of Smith et al. [30] should not be used to disparage APBI
using interstitial multi-catheter BT, if properly performed [4,11–
14,19,20,23–25,28].
Vaidya et al. [26] recently reported the interim results of an
international randomized trial comparing targeted intraoperative
RT (TARGIT) with WBI. At a median follow-up of two years, the
four-year estimate of LR was 1.2% in the TARGIT, and 0.95% in
the WBI group. The authors concluded that a single dose of RT
delivered at the time of surgery should be considered as an alter-
native to WBI. Another randomized trial (ELIOT Trial, Milan) was
currently being conducted using single-fraction intraoperative RT
[27]. However, further follow-up of the TARGIT and ELIOT trials
is necessary to prove the long-term efﬁcacy of single-fraction intra-
operative RT.
Our single-institution randomized trial represents the ﬁrst
phase III study proving that long-term results of PBI are similar
to WBI. At a median follow-up of 10.8 years, we failed to dem-
onstrate any statistically signiﬁcant difference in the ten-year
actuarial rates of LR, DFS, OS, and CSS between the two treat-
ment arms. However, with the LR rate of 5.9% (95% CI 1.6–
10.2%) in the PBI arm and 5.1% (95% CI 1.1–9.1%) in the WBI
arm, we cannot exclude that the PBI arm is inferior (or superior)
for our sample of 258. Although our results should be conﬁrmed
by ongoing multicentric phase III trials with larger sample size,
our ﬁndings reinforce the hypothesis that an accelerated RT reg-
imen conﬁned to a limited volume is safe, and more favorable
cosmetic outcome can be achieved with carefully designed
multi-catheter BT implants compared to the outcome after
WBI. A detailed analysis of late side-effects will be published
elsewhere. However we assume that the smaller irradiated vol-
ume and ﬁbrosis conﬁned to the tumor bed yielded less diffuse
ﬁbrosis and retraction in the APBI arm. In addition, skin side-
effects using properly performed interstitial implants practically
could be avoided. However, it should be emphasized that the
lack of modern teletherapy techniques (e.g. 3D-CRT and IMRT),and the use of cobalt units also contributed to the worse cos-
metic outcome in the WBI arm.
The main limitation of the present study is that due to the rel-
atively small sample size the statistical power might be limited for
the detection of small possible differences in local tumor control
between the two treatment arms. In spite of this limitation, the
ten-year results of our randomized study provide a strong basis
for other ongoing phase III APBI trials. Patient accrual for the
GEC-ESTRO multicentric phase III APBI trial was completed in
2009, and results are awaited to be published within two years.
Recruitment for the ongoing North-American NSABP B-39/RTOG
0413 APBI Trial was started in 2005. While the GEC-ESTRO Trial
compares WBI to APBI exclusively with multi-catheter interstitial
BT, the North-American Trial compares WBI to three different APBI
techniques including multi-catheter BT, single-catheter balloon BT,
and 3D-CRT. Recently, two additional phase III APBI trials have
been activated using 3D-CRT (the RAPID trial in Canada), and
intensity modulated RT (the IMPORT LOW trial in the UK) in the
PBI arm. Unfortunately, enrollment for the RAPID trial has been
prematurely closed.
In conclusion, the ten-year results of our randomized study
suggest that PBI using interstitial BT implants or electron beams
to deliver radiation to the tumor bed alone for a selected group
of early-stage breast cancer patients produce similar long-term
results to those achieved with conventional WBI. Signiﬁcantly bet-
ter cosmetic outcome can be achieved with carefully designed HDR
multi-catheter BT implants compared with the outcome after WBI.
Long-term results of other ongoing phase III APBI trials are needed
to deﬁne the role of different APBI techniques in the treatment of
early-stage breast cancer. As data from these trials mature, they
will hopefully support the integration of APBI into routine clinical
practice.Conﬂict of interest statement
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